Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

被引：63

作者：

da Cunha Colombo Bonadio, Renata Rodrigues ^{[1
]}

Fogace, Rodrigo Nogueira ^{[1
]}

Miranda, Vanessa Costa ^{[1
]}

Estevez Diz, Maria del Pilar ^{[1
]}

机构：

[1] Univ Sao Paulo, Inst Canc Estado Sao Paulo ICESP, Hosp Clin HCFMUSP, Fac Med, Sao Paulo, SP, Brazil

来源：

CLINICS | 2018年 / 73卷

关键词：

Ovarian Cancer; Homologous Recombination Deficiency; PARP Inhibitors; BRCA Mutation; OLAPARIB MAINTENANCE THERAPY; EPITHELIAL OVARIAN; SOMATIC MUTATIONS; BRCA MUTATION; COMBINED INHIBITION; FALLOPIAN-TUBE; DNA-REPAIR; PARP; CHEMOTHERAPY; COMBINATION;

D O I：

10.6061/clinics/2018/e450s

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and somatic mutations in other homologous recombination genes and epigenetic modifications, have also been implicated in homologous recombination deficiency. The epidemiology and implications of these other mechanisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Comprehension of the role of homologous recombination deficiency in ovarian cancer also allows the development of therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients.

引用

页数：6

共 52 条

[1] Somatic mutations in homologous recombination pathway genes in ovarian cancer. [J].

Aghajanian, Carol ;

DeLair, Deborah ;

Grisham, Rachel N. ;

Hensley, Martee Leigh ;

Konner, Jason A. ;

Makker, Vicky ;

O'Cearbhaill, Roisin Eilish ;

Sabbatini, Paul ;

Soumerai, Tara ;

Charen, Alexandra Snyder ;

Spriggs, David R. ;

Soslow, Robert A. ;

Tew, William P. ;

Zamarin, Dmitriy ;

Robson, Mark E. ;

Berger, Michael F. ;

Solit, David B. ;

Hyman, David Michael ;

Cadoo, Karen Anne .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[2] BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group [J].

Alsop, Kathryn ;

Fereday, Sian ;

Meldrum, Cliff ;

deFazio, Anna ;

Emmanuel, Catherine ;

George, Joshy ;

Dobrovic, Alexander ;

Birrer, Michael J. ;

Webb, Penelope M. ;

Stewart, Colin ;

Friedlander, Michael ;

Fox, Stephen ;

Bowtell, David ;

Mitchell, Gillian .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (21) :2654-2663

[3] Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors [J].

Antolin, Albert A. ;

Mestres, Jordi .

ONCOTARGET, 2014, 5 (10) :3023-3028

[4] Integrated genomic analyses of ovarian carcinoma [J].

Bell, D. ;

Berchuck, A. ;

Birrer, M. ;

Chien, J. ;

Cramer, D. W. ;

Dao, F. ;

Dhir, R. ;

DiSaia, P. ;

Gabra, H. ;

Glenn, P. ;

Godwin, A. K. ;

Gross, J. ;

Hartmann, L. ;

Huang, M. ;

Huntsman, D. G. ;

Iacocca, M. ;

Imielinski, M. ;

Kalloger, S. ;

Karlan, B. Y. ;

Levine, D. A. ;

Mills, G. B. ;

Morrison, C. ;

Mutch, D. ;

Olvera, N. ;

Orsulic, S. ;

Park, K. ;

Petrelli, N. ;

Rabeno, B. ;

Rader, J. S. ;

Sikic, B. I. ;

Smith-McCune, K. ;

Sood, A. K. ;

Bowtell, D. ;

Penny, R. ;

Testa, J. R. ;

Chang, K. ;

Dinh, H. H. ;

Drummond, J. A. ;

Fowler, G. ;

Gunaratne, P. ;

Hawes, A. C. ;

Kovar, C. L. ;

Lewis, L. R. ;

Morgan, M. B. ;

Newsham, I. F. ;

Santibanez, J. ;

Reid, J. G. ;

Trevino, L. R. ;

Wu, Y. -Q. ;

Wang, M. .

NATURE, 2011, 474 (7353) :609-615

[5] BRCA1 promoter methylation predicts adverse ovarian cancer prognosis [J].

Chiang, Jing Wang ;

Karlan, Beth Y. ;

Cass, Ilana ;

Baldwin, Rae Lynn .

GYNECOLOGIC ONCOLOGY, 2006, 101 (03) :403-410

[6] Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Coleman, Robert L. ;

Oza, Amit M. ;

Lorusso, Domenico ;

Aghajanian, Carol ;

Oaknin, Ana ;

Dean, Andrew ;

Colombo, Nicoletta ;

Weberpals, Johanne, I ;

Clamp, Andrew ;

Scambia, Giovanni ;

Leary, Alexandra ;

Holloway, Robert W. ;

Amenedo Gancedo, Margarita ;

Fong, Peter C. ;

Goh, Jeffrey C. ;

O'Malley, David M. ;

Armstrong, Deborah K. ;

Garcia-Donas, Jesus ;

Swisher, Elizabeth M. ;

Floquet, Anne ;

Konecny, Gottfried E. ;

McNeish, lain A. ;

Scott, Clare L. ;

Cameron, Terri ;

Maloney, Lara ;

Isaacson, Jeff ;

Goble, Sandra ;

Grace, Caroline ;

Harding, Thomas C. ;

Raponi, Mitch ;

Sun, James ;

Lin, Kevin K. ;

Giordano, Heidi ;

Ledermann, Jonathan A. .

LANCET, 2017, 390 (10106) :1949-1961

[7] A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study [J].

Coleman, Robert L. ;

Sill, Michael W. ;

Bell-McGuinn, Katherine ;

Aghajanian, Carol ;

Gray, Heidi J. ;

Tewari, Krishnansu S. ;

Rubin, Steven C. ;

Rutherford, Thomas J. ;

Chan, John K. ;

Chen, Alice ;

Swisher, Elizabeth M. .

GYNECOLOGIC ONCOLOGY, 2015, 137 (03) :386-391

[8] Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2, and RAD51C Status [J].

Cunningham, J. M. ;

Cicek, M. S. ;

Larson, N. B. ;

Davila, J. ;

Wang, C. ;

Larson, M. C. ;

Song, H. ;

Dicks, E. M. ;

Harrington, P. ;

Wick, M. ;

Winterhoff, B. J. ;

Hamidi, H. ;

Konecny, G. E. ;

Chien, J. ;

Bibikova, M. ;

Fan, J. -B. ;

Kalli, K. R. ;

Lindor, N. M. ;

Fridley, B. L. ;

Pharoah, P. P. D. ;

Goode, E. L. .

SCIENTIFIC REPORTS, 2014, 4

[9] BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer [J].

Dann, Rebecca Byler ;

DeLoia, Julie A. ;

Timms, Kirsten M. ;

Zorn, Kristin K. ;

Potter, Jennifer ;

Flake, Darl D., II ;

Lanchbury, Jerry S. ;

Krivak, Thomas C. .

GYNECOLOGIC ONCOLOGY, 2012, 125 (03) :677-682

[10] Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC) [J].

Elvin, Julia Andrea ;

He, Yuting ;

Sun, James ;

Odunsi, Kunle ;

Szender, James Brian ;

Moore, Kathleen N. ;

Gay, Laurie M. ;

Frampton, Garrett Michael ;

Vergilio, Jo-Anne ;

Suh, James ;

Ramkissoon, Shakti ;

Severson, Eric Allan ;

Daniel, Sugganth ;

Lin, Kevin K. ;

Hou, June YiJuan ;

Gunderson, Camille Catherine ;

Holman, Laura L. ;

Stephens, Phil ;

Raponi, Mitch ;

Ross, Jeffrey S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 6 →